Your browser doesn't support javascript.
loading
Chemical Proteomic Characterization of a Covalent KRASG12C Inhibitor.
Wijeratne, Aruna; Xiao, Junpeng; Reutter, Christopher; Furness, Kelly W; Leon, Rebecca; Zia-Ebrahimi, Mohammad; Cavitt, Rachel N; Strelow, John M; Van Horn, Robert D; Peng, Sheng-Bin; Barda, David A; Engler, Thomas A; Chalmers, Michael J.
Afiliación
  • Wijeratne A; Discovery Chemistry Research and Technologies and Oncology Research, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, United States.
  • Xiao J; Discovery Chemistry Research and Technologies and Oncology Research, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, United States.
  • Reutter C; Discovery Chemistry Research and Technologies and Oncology Research, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, United States.
  • Furness KW; Discovery Chemistry Research and Technologies and Oncology Research, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, United States.
  • Leon R; Discovery Chemistry Research and Technologies and Oncology Research, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, United States.
  • Zia-Ebrahimi M; Discovery Chemistry Research and Technologies and Oncology Research, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, United States.
  • Cavitt RN; Discovery Chemistry Research and Technologies and Oncology Research, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, United States.
  • Strelow JM; Discovery Chemistry Research and Technologies and Oncology Research, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, United States.
  • Van Horn RD; Discovery Chemistry Research and Technologies and Oncology Research, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, United States.
  • Peng SB; Discovery Chemistry Research and Technologies and Oncology Research, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, United States.
  • Barda DA; Discovery Chemistry Research and Technologies and Oncology Research, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, United States.
  • Engler TA; Discovery Chemistry Research and Technologies and Oncology Research, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, United States.
  • Chalmers MJ; Discovery Chemistry Research and Technologies and Oncology Research, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, United States.
ACS Med Chem Lett ; 9(6): 557-562, 2018 Jun 14.
Article en En | MEDLINE | ID: mdl-29937982
ABSTRACT
The KRASG12C protein product is an attractive, yet challenging, target for small molecule inhibition. One option for therapeutic intervention is to design small molecule ligands capable of binding to and inactivating KRASG12C via formation of a covalent bond to the sulfhydryl group of cysteine 12. In order to better understand the cellular off-target interactions of Compound 1, a covalent KRASG12C inhibitor, we have completed a series of complementary chemical proteomics experiments in H358 cells. A new thiol reactive probe (TRP) was designed and used to construct a cellular target occupancy assay for KRASG12C. In addition, the thiol reactive probes allowed us to profile potential off-target interactions of Compound 1 with over 3200 cysteine residues. In order to complement the TRP data we designed Compound 2, an alkyne containing version of Compound 1, to serve as bait in competitive chemical proteomics experiments. Herein, we describe and compare data from both the TRP and the click chemistry probe pull down experiments.

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: ACS Med Chem Lett Año: 2018 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: ACS Med Chem Lett Año: 2018 Tipo del documento: Article País de afiliación: Estados Unidos